Journal
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 15, Issue 5, Pages 576-590Publisher
SHENYANG PHARMACEUTICAL UNIV
DOI: 10.1016/j.ajps.2019.10.006
Keywords
Cancer; Vaccines; Nanotechnology; Antigens; Peptide; mRNA
Categories
Funding
- Shandong Province major scientific and technological innovation projects: the key technology of advanced pharmaceutics [2018CXGC1411]
Ask authors/readers for more resources
Vaccines therapeutics manipulate host's immune system and have broad potential for cancer prevention and treatment. However, due to poor immunogenicity and limited safety, fewer cancer vaccines have been successful in clinical trials. Over the past decades, nanotechnology has been exploited to deliver cancer vaccines, eliciting long-lasting and effective immune responses. Compared to traditional vaccines, cancer vaccines delivered by nanomaterials can be tuned towards desired immune profiles by (1) optimizing the physicochemical properties of the nanomaterial carriers, (2) modifying the nanomaterials with targeting molecules, or (3) co-encapsulating with immunostimulators. In order to develop vaccines with desired immunogenicity, a thorough understanding of parameters that affect immune responses is required. Herein, we discussed the effects of physicochemical properties on antigen presentation and immune response, including but not limited to size, particle rigidity, intrinsic immunogenicity. Furthermore, we provided a detailed overview of recent preclinical and clinical advances in nanotechnology for cancer vaccines, and considerations for future directions in advancing the vaccine platform to widespread anti-cancer applications. (C) 2020 Shenyang Pharmaceutical University. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available